Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Retinal Vein Occlusion - Pipeline Review, H2 2017 - Research and Markets
Business Wire (press release)
Retinal Vein Occlusion - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action ...

and more »

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related ...
Dove Medical Press
Purpose: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal ...


Expert Herald

Retinal Vein Occlusion Market Therapeutic Pipeline H2, Drug Profile and Major Key Players
Expert Herald
Retinal Vein Occlusion Market H2, latest research provides in depth analysis of Key players with pipeline review and targeted therapeutics covering drugs profile of Retinal Vein Occlusion industry. Retinal vein occlusion is a blockage in one of the ...
United States Retinal Vein Occlusion Therapeutics Market Report 2017satPRnews (press release)

all 2 news articles »

Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set
Nasdaq
We note that Eylea (aflibercept) is approved in the United States, the EU, Japan and other countries for the treatment of neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), macular edema following retinal vein ...

and more »

Retinal Vein Occlusion Therapeutics Market – Global Market Analysis Report 2017
MilTech
ReportsMonitor.com has added the report, “Global Retinal Vein Occlusion Therapeutics Market Research Report 2017.” The far reaching research study offers a 360-degree analysis of the market crosswise over different unequivocal elements, including ...

and more »

Retinal Vein Occlusion Market Trends Forecast Analysis by Manufacturers, Regions, Type and Application to 2025
MilTech
Retinal Vein Occlusion MarketFrom an insight perspective, the Retinal Vein Occlusion Market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views ...

and more »

ModernMedicine

Ultra-widefield angiography: New window for retinovascular features
ModernMedicine
Anti-vascular endothelial growth factor (anti-VEGF) therapy is the first-line therapy for physicians who treat patients with diabetic macular edema (DME) and macular edema related to retinal vein occlusion (RVO). The precise changes in the retinal ...


Newly designed method based on deep learning can detect macular fluid
Healio
An automated method based on deep learning to identify and quantify intraretinal cystoid fluid and subretinal fluid is an accurate digital analysis tool. Researchers developed a validated artificial intelligence method using deep learning to fully ...


Apex News

Retinal Vein Occlusion Therapeutics Market Clinical Analysis 2017 To 2022
Apex News
Global Retinal Vein Occlusion Therapeutics Market Research Report 2017 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly ...
Global Retinal Vein Occlusion Therapeutics Market 2017- Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc ...Observer of Press
EMEA (Europe, Middle East and Africa) Retinal Vein Occlusion Therapeutics Market Report 2017satPRnews (press release)

all 5 news articles »

Finance News Daily

Ohr Pharmaceuticals (OHRP) versus Compugen (CGEN) Head-To-Head Analysis
The Ledger Gazette
The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release ...
Ohr Pharmaceutical Incorporated (NASDAQ:OHRP)'s Trend Unknown, Especially After Increased ShortsFrisco Fastball

all 8 news articles »

Retinal Vein Occlusion Therapeutics Market trends estimates high demand by 2021
MilTech
Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after diabetic retinopathy. The RVO is mainly of two types based on the anatomy of the vein occlusion. The ...

and more »

Ims Capital Management Lowered Apple (AAPL) Stake By $2.80 Million; Regeneron Pharmaceuticals (REGN)'s ...
Hill Country Times
The Company's products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin ...

and more »

Clearside Biomedical (NASDAQ:CLSD) Upgraded to Hold by Zacks Investment Research
Dispatch Tribunal
According to Zacks, “Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products ...

and more »

Retinal Vein Occlusion Therapeutics Market grows with increasing in the investment in the healthcare sector
The Global Health News (press release) (blog)
Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after diabetic retinopathy. The RVO is mainly of two types based on the anatomy of the vein occlusion. The ...


Washington Post

Regeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail
Nasdaq
Regeneron Pharmaceuticals, Inc. 's REGN shares were down 2.7% on Monday following the announcement of its plan of not advancing the nesvacumab and Eylea combination study to phase III development. The decision was taken after two phase II studies ...
As AMD Race Tightens, Regeneron's Second Eye Drug Combo Falls ShortXconomy
Development of Eye Disease Combination Therapy Halted by Regeneron, Bayer after Phase II FailuresGenetic Engineering & Biotechnology News (press release)

all 29 news articles »

Westchester Capital Management Decreased Its Csx (Put) (CSX) Position; Coherus Biosciences (CHRS) Sellers ...
Norman Weekly
The Company's product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ's Disease, juvenile idiopathic arthritis, psoriasis ...

and more »

The Center for Biosimilars

Formycon Projects US Biosimilar Ranibizumab Launch in 2020
The Center for Biosimilars
If approved in the US marketplace, Formycon's drug will compete with Lucentis, which is approved to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and ...


Ozurdex for retinal vein occlusion approved in China
Healio
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...


Cardiovascular Business

Researchers confirm link between retinal vein occlusion, heart attack
Cardiovascular Business
In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase of 21 percent for suffering a heart attack. RVO is one of the most common causes of visual ...


National Institutes of Health (press release)

Avastin as effective as Eylea for treating central retinal vein occlusion
National Institutes of Health (press release)
Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI), part ...

and more »

The Pharmaceutical Journal

Bevacizumab as effective as aflibercept for central retinal vein occlusion
The Pharmaceutical Journal
Off-label drug is as effective as standard treatment for macular oedema, according to randomised controlled trial. Retinal image showing macular oedema. Source: Shutterstock.com. Researchers have demonstrated the efficacy of bevacizumab for treating ...


Elm Ridge Management Has Raised Apache (APA) Stake By $2.62 Million; Regeneron Pharmaceuticals (REGN)'s ...
San Times
The Company's products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin ...

and more »

Allergan Gets China Approval For Ozurdex To Treat Retinal Vein Occlusion
Nasdaq
(RTTNews.com) - Allergan plc ( AGN ) announced Monday that it has received an Imported Drugs License or IDL from the Chinese Food and Drug Administration or CFDA to market Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of adult ...
Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of ...PR Newswire (press release)

all 2 news articles »

Bevacizumab On Par With Aflibercept in Retinal Vein Occlusion
MedPage Today
Bevacizumab (Avastin) had similar visual acuity outcomes to aflibercept (Eylea) in patients who had macular edema from central retinal vein or hemiretinal vein occlusion, researchers found. In the SCORE2 trial, mean visual acuity letter score (VALS ...


Healio

Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion
Healio
Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion. Thalmon R. Campagnoli, MD; Gábor Márk Somfai, MD; Jing Tian, MD; Delia Cabrera DeBuc, MD; William E. Smiddy, MD. Ophthalmic Surgery, Lasers and Imaging ...


FlintDaily.com

A Reversal for Regeneron Pharmaceuticals, Inc. (REGN) Is Not Near. The Stock Rises Again
BZ Weekly
The Company's products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin ...
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks Investment Research

all 119 news articles »

News-Medical.net

Central Retinal Vein Occlusion (CRVO)
News-Medical.net
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss ...
US, UK trials underway to compare treatments for CRVOHealio

all 3 news articles »

Clearside Biomedical's TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein ...
GlobeNewswire (press release)
ALPHARETTA, Ga., June 08, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced that, today at the 40th Annual ...

and more »

Schneider Capital Management Decreased Its Terex (TEX) Stake; Ohr Pharmaceutical Has 1.25 Sentiment
NormanObserver.com
Schneider Capital Management Corp decreased Terex Corporation (TEX) stake by 61.47% reported in 2017Q2 SEC filing. Schneider Capital Management Corp sold 443,038 shares as Terex Corporation (TEX)'s stock rose 2.25%. The Schneider Capital Management ...

and more »

Widening use of dexamethasone implant for the treatment of macular edema
Dove Medical Press
Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious ...

» Load more